Pulmonary Hypertension Trial, Recruiting NCT06751082 Sponsor: Mayo Clinic Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT06751082
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You are currently being treated with a medication called sotatercept at the Mayo Pulmonary Hypertension Clinic

Who may not be able to join:

  • You are not able to give your own informed consent to participate in the study (for example, due to a cognitive or mental health condition that affects decision-making ability)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Robert Frantz, M.D., Mayo Clinic

Phone: 507-255-2648

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
20 January 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

EmPHasis10 Questionnaire; Number of pulmonary hypertension vasodilator medications taken by a subject; Number of patients to have a change in dose of prostanoid medications; Number of patient hospitalizations; Number of patients to cease therapy sessions; Number of patients to discontinue prostanoid therapy; Number of patients with bleeding complications; Number of patients to develop Skin telangiectasias; Change in 6 min walk distance; Number of patients to have a change in hemodynamics; Change in Right Ventricular Systolic Pressure (RVSP); Right Ventricular Strain; Change in Right Ventricle...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov